Alcidion (ASX:ALC) has acquired ExtraMed
Alcidion (ASX:ALC) has acquired ExtraMed Ltd., a UK provider of patient flow management software that helps address key pain-points for hospital administrative staff.
Alcidion is transforming healthcare with smart, intuitive and complementary software products and services that create a unique offering in the global healthcare market. It offers solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point-of-care to improve patient systems. Alcidion has delivered strong organic growth in FY20 (with solid revenue up 33% as of Q3). The acquisition of ExtraMed will further accelerate this growth profile. This will add nine NHS trusts (six being new to Alcidion), expanding its NHS presence to 27 trusts or ~19% of target Acute NHS market, with upside revenue potential on cross-sell opportunities for Miya (its flagship product).
ExtraMed is a long-standing UK market leader in patient flow and has a 20-year track record. It specializes in providing NHS trusts with software that helps frontline staff make informed decisions based on real-time visibility of patient flow.
Oaklins’ team in Australia acted as corporate advisor to the buyer in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more